

# Major R&D *milestones* in 2023

		<i>H1 2023</i>	<i>H2 2023</i>
<b>Dupixent</b>	COPD	<b>Positive</b> pivotal trial readout (BOREAS)	
	CIndU	<b>Efficacy criteria</b> not met	
<b>Oncology</b>	Sarclisa (1L MM, IMROZ)		Pivotal trial readout (IMROZ)
	tusamitamab ravtansine (LC03)		Interim analysis
<b>Neurology</b>	tolebrutinib		Moved to mid-2024 (event-driven)
<b>Rare Blood Disorders</b>	fitusiran (Hem A/B)		Pivotal trial readout
	ALTUVIIIIO (Hem A)	<b>U.S. approval</b>	
<b>Vaccines</b>	Beyfortus		<b>U.S. approval</b>